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This editorial refers to ‘Transcatheter aortic valve implant-
ation: early results of the FRANCE (FRench Aortic
National CoreValve and Edwards) registry’†, by
H. Eltchaninoff et al. on page 191 and ‘Transcatheter
aortic valve implantation: first results from a multi-centre
real-world registry’‡, by R. Zahn et al. on page 198
Degenerative aortic stenosis has become the most common valve
disease in Europe and the USA due to prolonged life expectancy
and associated degenerative effects on cardiac structures. It is
caused by an active pathobiological process which entails chronic
inflammation with lipoprotein deposition, osteoblast activation,
and extracellular calcification with bone formation.1 Progressive
valve obstruction due to immobilized leaflets results in pressure
overload, which in turn leads to left ventricular hypertrophy, col-
lagen deposition, relative ischaemia, and diastolic dysfunction
with pulmonary congestion (Figure 1). For several decades, surgical
aortic valve replacement (SAVR) has been considered the gold
standard in the treatment of symptomatic patients, resulting in
effective symptom relief and near normalization of prognosis.2
In the search for less invasive treatment modalities, the concept
of transcatheter implantation of heart valves was pioneered in
experimental models by Henning Andersen3 for the aortic and
Philipp Bonhoeffer4 for the pulmonary position, followed by the
first percutaneous human implant of an aortic valve prosthesis
by Alain Cribier5 in 2002. Since then, transcatheter aortic valve
implantation (TAVI) has revolutionized the management of patients
with severe aortic stenosis, with .10 000 implants performed to
date. The enthusiasm generated by TAVI relates to the simple but
convincing concept, a technique easily adopted by interventional
cardiologists, and a large unmet clinical need. While SAVR, in
analogy to most other medical procedures (i.e. percutaneous cor-
onary interventions), slowly progressed from low to higher risk
patient populations, the evolution of TAVI took the opposite
course, with early candidates being high risk surgical patients
with relevant co-morbidities judged to be ‘inoperable’. The
reproducible safety and efficacy data in published series of these
unfavourable patient populations (Table 1) not only increased confi-
dence in the technique but also established a novel, valuable treat-
ment option in the sizeable group of symptomatic patients with
severe aortic stenosis previously denied access to treatment.
Against this background, it is natural that indications will be tested
in less complex patient populations in the future, and TAVI enters
into competition with SAVR. In response to these developments,
the scientific community takes on the responsibility of defining the
framework, including unified clinical outcome definitions, rules of
data collection and validation, standardized echocardiographic assess-
ment, and design of appropriate registries and randomized trials.
Eltchaninoff et al.6 and Zahn et al.7 publish the results of two
moderate to large-scale national registries on TAVI in Europe in
this issue. Somewhat different in size, both registries have an
almost similar enrolment period starting in early 2009, are industry
independent, report data on both commercially available devices,
the Edwards Sapien balloon-expandable prosthesis (23 and 26 mm
prosthesis with 22–24 F delivery sheath) and the Medtronic Core-
Valve self-expanding device (26 and 29 mm prosthesis with 18 F
delivery sheath), and include all presently established access
options, namely the transfemoral, transapical, and trans-subclavian
access sites. Patients included in the registries were mainly octogen-
arians with a high prevalence of coronary and peripheral vascular
disease, previous cardiac surgery in a quarter of patients, and a
history of stroke in every 10th patient. Both studies corroborate
the results of previous reports (Table 1) in a real-world population
of consecutive patients within their respective countries, demon-
strating a technical success rate of 98–99%, similar 30-day mortality
of 12%, and an incidence of stroke of 3–4%.
What can we learn from these two studies? First, TAVI is associ-
ated with a high technical success rate using both devices in appro-
priately selected patients, and conversion to open surgery is
exceedingly rare. However, it would be misleading to conclude
that these procedures can be performed safely at sites without
cardiac surgery. A collaborative approach between invasive
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cardiologists and cardiac surgeons is of paramount importance for
the overall success of any TAVI programme. It not only provides a
safety net, but also safeguards against inappropriate patient selec-
tion and promotes discussion within the heart team, adds the tre-
mendous expertise of cardiac surgeons to the treatment of
complex patients with non-isolated aortic stenosis, and frequently
involves a team approach during the procedure itself. In addition,
the full exploitation of various access routes including the transapi-
cal and transsubclavian sites makes the involvement of cardiac sur-
geons invaluable. Secondly, the 30-day mortality of 12% in both
registries remains high. Although these figures may compare
favourably with expected mortality derived from the EuroScore
Figure 1 Centre: severe calcific aortic stenosis causes pressure overload followed by left ventricular hypertrophy, collagen deposition, rela-
tive ischaemia, and diastolic dysfunction with pulmonary congestion. Left top: transfemoral TAVI with implantation of the Edwards Sapien pros-
thesis. Left bottom: transapical TAVI with implantation of the Edwards Sapien prosthesis. Right top: transfemoral TAVI with implantation of the
Medtronic CoreValve prosthesis. Right bottom: transsubclavian TAVI with implantation of the Medtronic CoreValve prosthesis.
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Table 1 Demographics and outcome data of published single- and multicentre registries of TAVI using the Edwards Sapien and Medtronic CoreValve prostheses
Year of
publication
Type of
TAVI
Study
design
Device Total
patients, n
Age,
years
Logistic
EuroScore, %
Procedural
success, %
Procedural
mortality, %
30-day
mortality, %
30-day
stroke, %
Lichtenstein
et al.
2006 TA Single centre Edwards 7 80+7 35 100 – 14 0
Cribier et al. 2006 TF Single centre Edwards 36 80+7 27 75 7.4 22.2 3.7
Webb et al. 2006 TF Single centre Edwards 18 80+7 26.2+13.1 77.8 0 11.1 –
Grube et al. 2006 TF/TS Single centre CoreValve 25 80+7 11 84 – 20 12
Walther et al. 2007 TA Multicentre Edwards 59 80+7 27 93.2 13.6 13.6 3.4
Webb et al. 2007 TF Single centre Edwards 50 82+7 28 86 2 12 4
Grube et al. 2007 TF/TS Multicentre
(2)
CoreValve 86 82+6 21.7+12.6 88 6 12 10
Svensson et al. 2008 TA Multicentre Edwards 40 80+7 35.5 90 22.5 17.5 0
Piazza et al. 2008 TF/TS Multicentre CoreValve 646 81+7 23.1+13.8 97 1.5 8 1.9
Grube et al. 2008 TF/TS Single centre CoreValve 136 82+7 23.1+13.8 – 0 10.8 2.9
Walther et al. 2008 TA Single centre Edwards 50 82+5 27.6+12.2 94 0 8 0
Webb et al. 2009 TF/TA Single centre Edwards 168 84 28.6 94.1 1.2 11.3 4.2
Himbert et al. 2009 TF/TA Single centre Edwards 75 82+8 26+13 93.3 – 10 4
Osten et al. 2009 TF/TA Single centre Edwards 46 80+7 25.3 91 2.2 6.5 6.5
Thielmann et al. 2009 TF/TA Single centre Edwards 39 81+5 44.2+12.6 97 2.6 17.9 –
Bleiziffer et al. 2009 TF/TA/
TS
Single centre Edwards/
CoreValve
203 81+7 22+14 – – 11.2 7
Buellesfeld
et al.
2010 TF/TS Multicentre
(2)
CoreValve 168 80+7 23.8+15.4 90.5 – 11.9a –
Thomas et al. 2010 TF/TA Multicentre
(34)
Edwards 1038 80+7 25.7 (TF)/29.1 (TA) 93.8 – 8.5 2.5
Rode´s-Cabau
et al.
2010 TF/TA Multicentre
(6)
Edwards 339 80+7 – 93.3 1.7 10.4 2.3
Petronio et al. 2010 TF/TS Multicentre
(13)
CoreValve 514 83 20.1 98.6 0.8 5.4 1.8
Tchetche et al. 2010 TF Multicentre
(2)
Edwards/
CoreValve
45 81.8+4.2 25.2+8.4 97.8 2.2 4.4 0
aIn hospital.
TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral; TS, transsubclavian.
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and STS score as well as relative to the spontaneous clinical
course in untreated patients, clearly efforts to reduce mortality
further are needed. More than 80% of all reported deaths in
these series occurred during the first week and were largely
related to severe vascular complications. The advent of smaller
introducer and delivery systems will undoubtedly reduce the inci-
dence of these complications and the associated morbidity and
mortality. As both registries included a considerable number of
sites with no previous TAVI experience, it is likely that results
will improve further in experienced centres with high procedural
volume. The importance of the learning curve in reducing mor-
tality has been previously shown in single-centre series using
both the Edwards Sapien8 and the Medtronic CoreValve prosthe-
sis.9 Thirdly, the incidence of atrioventricular conduction disturb-
ances and the need for pacemaker implantation in 12–39% of
patients is notable. The anatomic proximity of the AV node and
His bundle to the valvular apparatus in conjunction with
balloon- and device-mediated injury and inflammation explain
the occurrence of this adverse event. In addition, device-specific
differences come into play, with a higher incidence of conduction
disturbances encountered with the Medtronic CoreValve prosthe-
sis possibly related to a deeper extension into the left ventricular
outflow tract as well as the self-expanding nature of its frame,10
which may apply a higher radial force and tissue stress in the
subannular region, particularly in the case of device–annulus mis-
match. Notwithstanding, the threshold for pacemaker implantation
varies widely according to clinical practice, as exemplified by a
pacemaker rate of 5% in the French and 21% in the German reg-
istry following implantation of the Edwards Sapien prosthesis,
which shows the need for widely accepted and uniform criteria
on pacemaker indications after TAVI procedures. In addition, pre-
cautionary measures such as the depth of the implantation of the
prosthesis, a less aggressive pre-dilatation regimen, and adequately
sized devices will help to reduce the rate of permanent pace-
makers. Fourthly, the haemodynamic short-term profiles of both
prostheses are excellent and similar to surgically implanted
valves in terms of transvalvular gradient as well as effective
orifice area, and accompanied by symptomatic improvement and
improved left ventricular function. Conversely, TAVI remains
associated with more frequent paravalvular regurgitation as com-
pared with SAVR whose long-term sequelae require careful
study.11 Fifthly, TAVI is a catheterization laboratory-based tech-
nique with more than two-thirds of procedures performed in
this environment in the French registry. While some advocate
hybrid operating suites as the optimal location to perform TAVI,
reality as reflected in the French registry and future developments
with smaller delivery systems may outpace institutional hurdles
and cost-related delays in the timely establishment of other set-
tings. Finally, TAVI is a highly versatile technique, which, by
means of various access routes including the transfemoral, transa-
pical, and transsubclavian site, allows for a broad clinical applica-
bility in the majority of patients (Figure 1). Both devices play a
complementary role and currently accommodate a valve annulus
ranging from 19 to 27 mm largely independent of the take-off of
the coronary arteries, and a wider range of device sizes will
allow the indications to be extended to even smaller and larger
aortic annuli in the near future.
There are several limitations which should be considered when
interpreting the presented data. In both registries, the two devices
as well as the access routes have been used according to the dis-
cretion of the operator, rendering the results of multiple fairly
small subgroups less meaningful. Moreover, both registries report
only short-term clinical outcome data at 1 month, which are
important to define device safety, but are clearly insufficient to
delineate the efficacy profile of this technology. In addition, the
data assembled in both registries become outdated with the
advent of new device iterations. The newest generation Edwards
SAPIEN XT prosthesis has a lower profile (NovaFlex delivery
system) and is delivered through 18/19 F sheaths. The next iter-
ation of the Medtronic CoreValve device uses the Accutrak
feature for improved stability upon device placement. Finally, the
lack of data monitoring, independent event adjudication, differ-
ences in event reporting as well as inconsistent outcome defi-
nitions provide additional sources of relevant bias. Future studies
in the field of TAVI will benefit from the consensus on standardized
outcome definitions, the results of which are published in this issue
by Leon and colleagues12 and have been assembled under the
umbrella of the Valve Academic Research Consortium (VARC)
representing several Academic Research Organizations, Surgical
and Cardiological Professional Societies, members of the US
Food & Drug Administration, and independent experts. This
achievement must be followed by properly conducted randomized
clinical trials comparing TAVI with the established gold standard
therapy of SAVR before further expanding the indications for
TAVI towards lower risk patient populations.
TAVI has led to a paradigm shift in the management of patients
with aortic stenosis at high risk for SAVR. Its full potential will
unfold during the upcoming years of continued technical refine-
ments and clinical investigation. The intense research activities
including numerous TAVI registries, ongoing randomized clinical
trials, and efforts such as VARC are taking place during a period
where this technology is still in its infancy. They are the foundation
of what may evolve into a field of unprecedented wealth and
quality of clinical research, guiding physicians in the selection of
the most appropriate treatment for their patients.
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Double orifice mitral valve with normal function: an echocardiography
and MRI study of a rare finding
Frank van Buuren*, Lothar Faber, and Nikola Bogunovic
Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Georgstr. 11, 32545 Bad Oeynhausen, Germany
* Corresponding author. Tel: +49 5731 971258, Fax: +49 5731 972194, Email: fvbuuren@hdz-nrw.de
Double orifice mitral valve (DOMV) is a rare congenital lesion
often associated with other abnormalities such as bicuspid
aortic valve or aortic coarctation. Also abnormalities of the sub-
valvular apparatus such as malformation of chordae tendineae
(abnormal attachment, parachute type, etc.) and papillary
muscles are found frequently. The atrio-ventricular connection
consists of two anatomically distinct orifices separated by acces-
sory fibrous tissue. In about 50% of DOMV cases, valvular func-
tion is normal, others present with stenosis or regurgitation. In
most cases (85%), a larger orifice is accompanied by a small
eccentric accessory orifice, 15% (see our case) show duplicated
mitral valves (MVs). Embryologically, the lesion results from
abnormal leaflet fusion and persistence of the left part of the
common atrio-ventricular canal.
We present a 59-year-old male patient with DOMV and coex-
isting stenotic bicuspid aortic valve, a low gradient aortic coarctation, and normal MV function. Parasternal 2D cross-sectional echo-
cardiography (Panel A) demonstrates two MV orifices (1./2.), a modified apical four-chamber view shows four leaflets and two
separated diastolic left ventricular inflow jets (Panel B). Three-dimensional echocardiography (Panel C) and MRI imaging in the two-
chamber view (Panel D, Supplementary material online, Video S1) confirmed the central fibrous bridge dividing the atrio-ventricular
orifice. The mild aortic coarctation is demonstrated in Supplementary material online, Video S2.
In cases of severely dysfunctional DOMV with stenosis or regurgitation, surgical intervention is recommended. In cases with normal
MV function, surgical therapy is eventually necessary to repair the associated cardiac lesion. In our patient, aortic valve replacement
and closure of a coexisting ASD were performed uneventfully.
RV, right ventricle; LV, left ventricle; LA, left atrium; Ao desc, aorta descendens.
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